Our Areas of Activity
Driven by the exponential power of a life worth living.
Where
there's a will,
there's a way.
Product Development
We manage over 4000 marketing authorizations globally and have developed over 130 products that are marketed worldwide.
Business Development
In-Licensing and Out-Licensing are part of our strategic axis with a view to strengthening the portfolio of all our subsidiaries, business areas, and areas of expertise.
Production
Our manufacturing operations are supported by two production centres of excellence, Atlantic Pharma and Atlas Pharm, which are committed to innovation and quality.
Commercial partnerships
We are continuously exploring new strategic partnerships that deliver innovative healthcare products with the highest quality standards.
Partnerships
Our partnerships, which extend across most of Europe, Africa, Asia, the Middle East, Oceania, and North and South America, allow us to grow both locally and globally.
Where
there's a will,
there's a way.
Product Development
We manage over 4000 marketing authorizations globally and have developed over 130 products that are marketed worldwide.
Business Development
In-Licensing and Out-Licensing are part of our strategic axis with a view to strengthening the portfolio of all our subsidiaries, business areas, and areas of expertise.
Production
Our manufacturing operations are supported by two production centres of excellence, Atlantic Pharma and Atlas Pharm, which are committed to innovation and quality.
Commercial partnerships
We are continuously exploring new strategic partnerships that deliver innovative healthcare products with the highest quality standards.
Partnerships
Our partnerships, which extend across most of Europe, Africa, Asia, the Middle East, Oceania, and North and South America, allow us to grow both locally and globally.
At Tecnimede Group, a dedicated
team of over 750 professionals works
tirelessly to shape the future of
healthcare. United by a common
purpose, we are committed to
safeguarding the health and well-being
of every individual.
Continuously driven by innovation,
we actively seek new partnerships
to develop groundbreaking
healthcare solutions that make a
difference.
Discover some of Tecnimede Group’s ongoing R&D projects
Research and development of own fixed combinations
Tecnimede Group researches and develops its own fixed combinations with the purpose of developing new drugs that contribute to improving the health and quality of life of people. The combination of active substances within a single pharmaceutical formulation may present several advantages, including, among others, the improvement of therapeutic compliance or the enhancement of the therapeutic effect resulting from the combination of the drugs.
Development and provision of generic medication
Generic drugs are drugs with the same qualitative and quantitative composition in terms of active substances and the same pharmaceutical form as the reference drug. The bioequivalence of generic drugs in relation to the reference drug has also been guaranteed through appropriate bioavailability studies. The Tecnimede Group develops about a dozen new generic drugs every year.
The development and availability of generic medicines enables national healthcare systems and the user to save very considerable amounts of money while ensuring the safety, efficacy, and quality of the medicine.
The billions of euros of savings that generic medicines produce every year boost the sustainability of healthcare systems, improve the accessibility of medicines to the population, free up capital for essential treatments and services for patients, and stimulate research into new therapeutic solutions.
Research into new chemical entities for new drugs
The Tecnimede Group, with the purpose of developing new drugs that contribute to improving people's health and quality of life, researches and develops new chemical entities that enable the treatment of the most relevant conditions affecting society, with particular emphasis on infectious diseases and nervous system diseases. The varied patented chemical entities available to our scientists and researchers ensure they work every day to find new and improved solutions to meet the population’s needs.
Discover some of Tecnimede Group’s ongoing R&D projects
Research and development of own fixed combinations
Tecnimede Group researches and develops its own fixed combinations with the purpose of developing new drugs that contribute to improving the health and quality of life of people. The combination of active substances within a single pharmaceutical formulation may present several advantages, including, among others, the improvement of therapeutic compliance or the enhancement of the therapeutic effect resulting from the combination of the drugs.
Development and provision of generic medication
Generic drugs are drugs with the same qualitative and quantitative composition in terms of active substances and the same pharmaceutical form as the reference drug. The bioequivalence of generic drugs in relation to the reference drug has also been guaranteed through appropriate bioavailability studies. The Tecnimede Group develops about a dozen new generic drugs every year.
The development and availability of generic medicines enables national healthcare systems and the user to save very considerable amounts of money while ensuring the safety, efficacy, and quality of the medicine.
The billions of euros of savings that generic medicines produce every year boost the sustainability of healthcare systems, improve the accessibility of medicines to the population, free up capital for essential treatments and services for patients, and stimulate research into new therapeutic solutions.
Research into new chemical entities for new drugs
The Tecnimede Group, with the purpose of developing new drugs that contribute to improving people's health and quality of life, researches and develops new chemical entities that enable the treatment of the most relevant conditions affecting society, with particular emphasis on infectious diseases and nervous system diseases. The varied patented chemical entities available to our scientists and researchers ensure they work every day to find new and improved solutions to meet the population’s needs.
Discover some of Tecnimede Group’s ongoing R&D projects
Research and development of own fixed combinations
Tecnimede Group researches and develops its own fixed combinations with the purpose of developing new drugs that contribute to improving the health and quality of life of people. The combination of active substances within a single pharmaceutical formulation may present several advantages, including, among others, the improvement of therapeutic compliance or the enhancement of the therapeutic effect resulting from the combination of the drugs.
Development and provision of generic medication
Generic drugs are drugs with the same qualitative and quantitative composition in terms of active substances and the same pharmaceutical form as the reference drug. The bioequivalence of generic drugs in relation to the reference drug has also been guaranteed through appropriate bioavailability studies. The Tecnimede Group develops about a dozen new generic drugs every year.
The development and availability of generic medicines enables national healthcare systems and the user to save very considerable amounts of money while ensuring the safety, efficacy, and quality of the medicine.
The billions of euros of savings that generic medicines produce every year boost the sustainability of healthcare systems, improve the accessibility of medicines to the population, free up capital for essential treatments and services for patients, and stimulate research into new therapeutic solutions.
Research into new chemical entities for new drugs
The Tecnimede Group, with the purpose of developing new drugs that contribute to improving people's health and quality of life, researches and develops new chemical entities that enable the treatment of the most relevant conditions affecting society, with particular emphasis on infectious diseases and nervous system diseases. The varied patented chemical entities available to our scientists and researchers ensure they work every day to find new and improved solutions to meet the population’s needs.
- Portugal
- Spain
- Italy
- Morocco
- Colombia
- Brazil
Pharmaceutical company
100% funded by Portuguese
private capital.
- Portugal
- Spain
- Italy
- Morocco
- Colombia
- Brazil
Pharmaceutical company
100% funded by Portuguese
private capital.